Alpha 1 Adrenergic Receptor Antagonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Alpha 1 Adrenergic Receptor Antagonists are a class of pharmaceutical drugs that target and block α1 adrenergic receptors found on smooth muscle cells. By inhibiting the activation of these receptors by endogenous catecholamines, they promote smooth muscle relaxation. α1 Adrenergic Receptor Antagonists are primarily used in the treatment of conditions such as benign prostatic hyperplasia (BPH) and hypertension, where smooth muscle contractions play a role in the pathophysiology of these diseases. According to WHO, BPH affects approximately 50% of men over the age of 50 and over 90% of men over 80. It is estimated that 15% of men with BPH will develop lower urinary tract symptoms severe enough to require medical treatment. In Europe, BPH affects around 30% of men aged 50-59 and 80% of men aged 70-79. The prevalence of hypertension is also significant, with around 30% of adults in Europe and 45% of adults in the United States having this condition. Hypertension is a major risk factor for cardiovascular diseases.

The growth drivers of the α1 Adrenergic Receptor Antagonists market include advancements in drug research and development, increasing healthcare expenditure, and a growing aging population. The development of innovative and more effective α1 Adrenergic Receptor Antagonists, along with expanding therapeutic indications, contributes to the market's growth. Additionally, the rising prevalence of conditions such as BPH and hypertension, particularly among the aging population, creates a sustained demand for these medications. Companies such as Tonix, Lundbeck, Ocuphire Pharma, Chong Kun Dang, Simcere, Pharmazz, Ache Lab, Abbott, and Otsuka cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Otsuka is currently conducting a clinical trial of the drug ACH-000029 for the treatment of BPH.

Key Developments

• In April 2023, Bristol-Myers Squibb’s generic drug Aripiprazole got US FDA approval for the maintenance therapy of bipolar disorders
• In July 2021, OWP Pharmaceuticals has patent protection for quetiapine oral liquid suspension in the USA

Approved α1 Adrenergic Receptor Antagonists Molecules

• Aripiprazole
• Quetiapine
• Tamsulosin
• Paliperidone extended release
• Prazosin
• Silodosin
• Terazosin

Alpha 1 Adrenergic Receptor Antagonists Pipeline Molecules

• Centhaquin (PMZ2010)
• ACH-000029

Clinical Activity and Development of Alpha 1 Adrenergic Receptor Antagonists

In the α1 adrenergic receptor antagonists space, few companies, conducting more than 50 clinical trials in this category of drugs. For instance,

• In July 2023, OWP Pharmaceuticals initiated clinical trials of Quetiapine oral suspension in bipolar disorders in the USA
• In April 2023, Otsuka Pharmaceutical released safety and pharmacokinetics data from a phase I trial of Aripiprazole in Bipolar disorder and Schizophrenia